OpenEvidence hits $12B valuation as specialized medical AI demand doubles in months
OpenEvidence has achieved a $12B valuation after a $250M Series D round. Learn how this medical AI platform for doctors doubled its value and surpassed $100M in revenue.
In just three months, its market value has doubled. Medical AI powerhouse OpenEvidence has reached a staggering $12 billion valuation, proving that Silicon Valley is placing its biggest bets on deep, vertical expertise rather than broad, general-purpose AI.
OpenEvidence hits $12B valuation via Series D milestone
According to TechCrunch, OpenEvidence announced on Wednesday that it's raised $250 million in a Series D funding round co-led by Thrive Capital and DST. This new injection of capital values the startup at $12 billion, a 100% jump from its $6 billion valuation in October 2025. The company has now raised a total of $700 million to date.
Surpassing $100M in revenue through clinician trust
While many AI startups struggle with monetization, OpenEvidence has already surpassed the $100 million revenue mark. Its platform served 18 million clinical consultations from verified U.S. healthcare professionals in December 2025 alone—a massive spike from the 3 million monthly searches recorded just a year prior.
Winning the healthcare AI war against giants
Investors don't seem worried about competition from OpenAI or Anthropic. OpenEvidence's laser focus on doctor-facing clinical information sets it apart from Anthropic's broader 'Claude for Healthcare' and ChatGPT's consumer-centric health products. The startup's ability to win over skeptical medical professionals gives it a moat that general models haven't yet breached.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Eat App secures $10M for its India expansion. Learn how the Dubai-based startup is partnering with Swiggy and acquiring ReserveGo to dominate the $85B market.
Chai Discovery lands a $1.3B valuation and partners with Eli Lilly for AI-powered drug discovery. Explore the OpenAI-backed startup's journey and its Chai-2 algorithm.
Exploring the reality of medical AI accuracy as portrayed in 'The Pitt' Season 2. Analyzing OpenAI's GPT-5.2 hallucination rates and the role of AI in hospitals.
Berlin-based AI startup Parloa raises $350M in Series D funding, reaching a $3B valuation in less than a year. Learn how they plan to disrupt the customer service market.
Eat App secures $10M for its India expansion. Learn how the Dubai-based startup is partnering with Swiggy and acquiring ReserveGo to dominate the $85B market.
Chai Discovery lands a $1.3B valuation and partners with Eli Lilly for AI-powered drug discovery. Explore the OpenAI-backed startup's journey and its Chai-2 algorithm.
Exploring the reality of medical AI accuracy as portrayed in 'The Pitt' Season 2. Analyzing OpenAI's GPT-5.2 hallucination rates and the role of AI in hospitals.
Berlin-based AI startup Parloa raises $350M in Series D funding, reaching a $3B valuation in less than a year. Learn how they plan to disrupt the customer service market.